The generic name, dosage, duration, and reason for the concomitant medication should be included in this report. The following therapies are not permitted during the study (if administered, the subject may be removed from the study): • Non-study chemotherapy or immunotherapy (approved or investigational) • TNF pathway inhibitors or PI3 kinase inhibitors • Systemically active steroids for more than 3 days or use of any systemic steroids within 14 days before or after dosing, with exception of study - prescribed steroids • Any other investigational product • Filgrastim (Neupogen or G -CSF) or Sargramostin (Leukine or GM -CSF) should not be administered 14 days prior to or 14 days after any CRS -207 dose. Approva l must be obtained from the medical monitor for a subject to continue dosing if administered within this timeframe. • Prophylactic vaccines (e.g. pneumococcal vaccine, influenza vaccine) should not be administered 28 days prior to or 28 days after any CRS -207 dose. Approval must be obtained from the medical monitor for a subject to continue dosing if a prophylactic vaccine is administered within this timeframe. In addition, the following therapies should not be administered during the study unless medically necessary and approval must be obtained from the medical monitor for a subject to continue dosing if therapy is given concurrently with study participation: • General anesthesia or deep sedation • Aspirin >325 mg/d (chronic daily use of aspirin ≤325 mg/d and heparin flushes for central lines are allowed) • More than 4 g/d of acetaminophen Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 28 • Systemic antibiotics If subjects receive immunosuppressive medications on or after study, prophylactic antibiotics to prevent CRS -207 infection are strongly recommended for the duration of the treatment with the immunosuppressant (recommended oral 80 mg trimethoprim / 400 mg sulfamethoxazole once daily or 160 mg trimethoprim / 800 mg sulfamethoxazole (DS) three days a week). Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 29 5.0 EXPERIMENTAL PROCEDURES 5.1 OVERVIEW: SCHEDULE OF TIME AND EVENTS An overview of study time and events for Cohort 1 is presented in Table 2 a and for Cohort 2 in Table 2b . Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 30 Table 2a. CRS -207 and Pemetrexed/Cisplatin [Cohort 1] Nominal Weeks (Wk)a Screening Wk 1 Wk 3 Wk 5 Wk 8 Wk 11 Wk 14 Wk 17 Wk 20 Wk 23 Wk 26 Wk 30 Follow -up: 4 wks after EOC then every 8 wksb Visit ID SCR PV1 PV2 CY 1 CY 2 CY 3 CY 4 CY 5 CY 6 BV1 BV2 EOC FU/EOS Cycle Study Day (-28) 1 2 8 1 2 8 1 1 1 1 1 1 1 2 8 1 2 8 1 1 Visit Windows (days) - - ±1 - - ±1 - - - - - - - - ±1 - - ±1 +7 ±7 Informed consent X Inclusion/exclusion X Medical history, medication history X Cancer -related treatment X Baseline signs/symptoms X Virology screen c X Coagulation panel, UA d X Pulmonary Function Test e X Electrocardiogram, 12 -lead X X CT, tumor asses s.; optional FDG -PET f X X X X X X Physical examination g X X X X X X X X X X X X X ECOG performance status X X X X X X X X X X X X X Vital signs, pulse oximetry, weight , height h X X X X X X X X X X X X X X X X X Pregnancy test i X X X X X X CD4 count X X Creatinine clearance j X Clinical hematology, serum chemistry k,l X X X X X X l X l X l X l X l X l X X X X X X Tumor marker(s) m X X X X X X X X X X X X Concomitant medications, AEs n X X Xn X X Xn X X X X X X X X Xn X X Xn X X PBMC o X X X X X X Serum for Lm/mesothelin immunityp X X X X X X X X X X HLA -typing q X Archival tissue Xr Tumor biopsy (optional) s X X X X Antibiotics t X Xu Blood sample for CRS -207 testing Xv Study Drug Administration CRS-207 w,x X X X X Xu Pemetrexed/ cisplatin y, z X X X X X X Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 31 Footnotes: a Study schedule and timing displayed is based on the subject completing the full treatment regimen of 6 chemotherapy cycles. However, subjects may receive CRS- 207 boost vaccinations if they complete between 4 -6 cycles in which case the visit timing will be modified. If CRS-207 doses or chemotherapy cycles are delayed, subsequent dosing schedule will be adjusted according to the delayed dose(s). b Follow -up visit to occur 4 weeks after EOC then every 8 weeks until treatment discontinuation. EOS Visit will occur within 4 weeks after the last dose of study drug or prior to commencing the new therapy. If the EOS visit occurs earlier than 4 weeks, a safety follow- up telephone call on Day 28 (+/- 7 days) is required; document contact in the study records. c Virology screen will be performed if one has not been done within 14 days before screening: HIV antibody, hepatitis B surface antigen, and hepatitis C antibody (exception: clear evidence of natural immunity, immunity subsequent to vaccination, or successful eradication of the virus following antiviral therapy); additional virology may also be evaluated. d Coagulation panel includes the following: prothrombin time (PT), international normalized ratio of prothrombin time (INR), activated partial thromboplastin time (APTT); UA includes the following: bilirubin, blood, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity. e Pulmonary function tests (PFTs) to include VC , FVC and FEV 1.